Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
207.8 EUR | -0.19% | +2.26% | +14.43% |
Jun. 05 | ESSILORLUXOTTICA : Gets a Neutral rating from RBC | ZD |
May. 31 | ESSILORLUXOTTICA : Oddo BHF confirms its recommendation on the stock | CF |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 35.07 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 3.76 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company is highly valued given the cash flows generated by its activity.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+14.43% | 103B | B | ||
+0.68% | 18.76B | B- | ||
-22.01% | 2.25B | D+ | ||
+20.57% | 2.05B | C+ | ||
+21.94% | 1.18B | - | ||
-43.86% | 670M | - | ||
-9.93% | 662M | - | ||
-45.17% | 638M | B- | ||
+56.37% | 595M | - | - | |
+28.57% | 545M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EL Stock
- Ratings EssilorLuxottica